{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:51:55Z","timestamp":1790887915031,"version":"4.1.0"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Richter transformation (RT), defined as the development of an aggressive lymphoma on a background of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), represents a clinical unmet need because of its dismal prognosis. An increasing body of knowledge in the field of RT is arising from the recent development of preclinical models depicting the biology underlying this aggressive disease. Consistently, new therapeutic strategies based on a genetic <jats:italic>rationale<\/jats:italic> are exploring actionable pathogenic pathways to improve the outcome of patients in this setting. In this review, we summarize the current understandings on RT biology and the available treatment options.<\/jats:p>","DOI":"10.3389\/fonc.2022.829983","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T19:28:03Z","timestamp":1648409283000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":54,"title":["Biology and Treatment of Richter Transformation"],"prefix":"10.3389","volume":"12","author":[{"given":"Adalgisa","family":"Condoluci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Ed","author":"Swerdlow","year":"2017"},{"key":"B2","article-title":"Generalized Reticular Cell Sarcoma of Lymph Nodes Associated With Lymphatic Leukemia","volume":"4","author":"Richter","year":"1928","journal-title":"Am J Pathol"},{"key":"B3","article-title":"Chronic Lymphoid Leukemia Secondarily Associated With a Malignant Reticulopathy: Richter's Syndrome","volume":"4","author":"Lortholary","year":"1964","journal-title":"Nouv Rev Fr Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12458","article-title":"Diffuse Large B-Cell Lymphoma (Richter Syndrome) in Patients With Chronic Lymphocytic Leukaemia (CLL): A Cohort Study of Newly Diagnosed Patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e235816","DOI":"10.1136\/bcr-2020-235816","article-title":"Transformation to Plasmablastic Lymphoma in CLL Upon Ibrutinib Treatment","volume":"13","author":"Marvyin","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16748","article-title":"Clinical Outcome and Prognostic Factors of Patients With Richter Syndrome: Real-World Study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"128e33","DOI":"10.1016\/j.canep.2019.04.002","article-title":"Richter Syndrome Epidemiology in a Large Population Based Chronic Lymphocytic Leukemia Cohort From Norway","volume":"60","author":"Lenartova","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1036e43","DOI":"10.1002\/ajh.24473","article-title":"Histologic Transformation of Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"91","author":"Agbay","year":"2016","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter Transformation in Chronic Lymphocytic Leukemia (CLL)-A Pooled Analysis of German CLL Study Group (GCLLSG) Front Line Treatment Trials","volume":"35","author":"Al-Sawaf","year":"2020","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter's Transformation of Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL): An Analysis of the SEER Database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/%25x","article-title":"Aberrant Somatic Hypermutation in Transformation of Follicular Lymphoma and Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","volume":"91","author":"Rossi","year":"2006","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23939","article-title":"Hodgkin Transformation of Chronic Lymphocytic Leukemia: Incidence, Outcomes, and Comparison to De Novo Hodgkin Lymphoma","volume":"90","author":"Parikh","year":"2015","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal Evolution Leading to Ibrutinib Resistance in Chronic Lymphocytic Leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients With Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens Versus Chemoimmunotherapy in Older Patients With Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab in First-Line Treatment of Chronic Lymphocytic Leukaemia (iLLUMINATE): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib With or Without Obinutuzumab Versus Chlorambucil and Obinutuzmab for Treatment-Naive Chronic Lymphocytic Leukaemia (ELEVATE TN): A Randomised, Controlled, Phase 3 Trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630947","article-title":"A Phase 2 Study of Idelalisib Plus Rituximab in Treatment-Na\u00efve Older Patients With Chronic Lymphocytic Leukemia","volume":"126","author":"O\u2019Brien","year":"2015","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030221","article-title":"Efficacy Results of a Phase 2 Trial of First-Line Idelalisib Plus Ofatumumab in Chronic Lymphocytic Leukemia","volume":"3","author":"Lampson","year":"2019","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients With CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal Evolution Underlying Leukemia Progression and Richter Transformation in Patients With Ibrutinib-Relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-4004","article-title":"Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses","volume":"78","author":"Vaisitti","year":"2018","journal-title":"Cancer Res"},{"key":"B24","article-title":"Detection of Richter's Transformation of Chronic Lymphocytic Leukemia by PET\/Ct","volume":"47","author":"Bruzzi","year":"2006","journal-title":"J Nucl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2222","article-title":"The Pathology of Transformation of Indolent B Cell Lymphomas","author":"Gascoyne","year":"2015","journal-title":"Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation Between FDG\/PET, Histology, Characteristics, and Survival in 332 Patients With Chronic Lymphoid Leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.21","article-title":"Diagnostic and Prognostic Role of PET\/CT in Patients With Chronic Lymphocytic Leukemia and Progressive Disease","volume":"29","author":"Mauro","year":"2015","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1099643","article-title":"An 18f-FDG-PET Maximum Standardized Uptake Value\u2009>\u200910 Represents a Novel Valid Marker for Discerning Richter's Syndrome","volume":"57","author":"Michallet","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B29","doi-asserted-by":"publisher","first-page":"Abstract 834","DOI":"10.1182\/blood.V130.Suppl_1.834.834","article-title":"Analysis of PET-CT to Identify Richter\u2019s Transformation in 167 Patients With Disease Progression Following Kinase Inhibitor Therapy","volume":"130","author":"Mato","year":"2017","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-302174","article-title":"The Genetics of Richter Syndrome Reveals Disease Heterogeneity and Predicts Survival After Transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/his.13024","article-title":"Diagnostic Dilemmas of High-Grade Transformation (Richter's Syndrome) of Chronic Lymphocytic Leukaemia: Results of the Phase II National Cancer Research Institute CHOP-OR Clinical Trial Specialist Haemato-Pathology Central Review","volume":"69","author":"Soilleux","year":"2016","journal-title":"Histopathology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and Highly Active Proliferation Centers Identify a Histological Subtype of Chronic Lymphocytic Leukemia (\"Accelerated\" Chronic Lymphocytic Leukemia) With Aggressive Clinical Behavior","volume":"95","author":"Gin\u00e9","year":"2010","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-Cell Receptor is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH Mutational Status and Clonality Analysis of Richter\u2019s Transformation","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 Expression in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL) and Large B-Cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15514","article-title":"PD-1 is Highly Expressed by Neoplastic B-Cells in Richter Transformation","volume":"185","author":"Behdad","year":"2019","journal-title":"Br J Haematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131448","article-title":"Genetic Lesions Associated With Chronic Lymphocytic Leukemia Transformation to Richter Syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J Exp Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two Main Genetic Pathways Lead to the Transformation of Chronic Lymphocytic Leukemia to Richter Syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.723706","article-title":"MGA, a Suppressor of MYC, Is Recurrently Inactivated in High Risk Chronic Lymphocytic Leukemia","volume":"54","author":"De Paoli","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008276","article-title":"B-Cell Receptor Signaling and Genetic Lesions in TP53 and CDKN2A\/CDKN2B Cooperate in Richter Transformation","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-603217","article-title":"Excessive Antigen Reactivity may Underlie the Clinical Aggressiveness of Chronic Lymphocytic Leukemia Stereotyped Subset 8","volume":"125","author":"Gounari","year":"2015","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 Are an Independent Predictor of Survival in Chronic Lymphocytic Leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09155.x","article-title":"Different Impact of NOTCH1and SF3B1 Mutations on the Risk of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome","volume":"158","author":"Rossi","year":"2012","journal-title":"Br J Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 Mutations Identify a Genetic Subgroup of Chronic Lymphocytic Leukemia Patients With High Risk of Transformation and Poor Outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and Transcriptomic Correlates of Richter Transformation in Chronic Lymphocytic Leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41408-021-00477-5","article-title":"Distinct Immune Signatures in Chronic Lymphocytic Leukemia and Richter Syndrome","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in Patients With CLL and Richter Transformation or With Relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying Cancers Based on T-Cell Infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination Cancer Immunotherapies Tailored to the Tumour Microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17789","article-title":"Characterisation of Immune Checkpoints in Richter Syndrome Identifies LAG3 as a Potential Therapeutic Target","volume":"195","author":"Gould","year":"2021","journal-title":"Br J Haematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of Disease Within 24 Months in Follicular Lymphoma is Associated With Reduced Intratumoral Immune Infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005734","article-title":"Active Akt Signaling Triggers CLL Toward Richter Transformation via Overactivation of Notch1","volume":"137","author":"Kohlhaas","year":"2021","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/382635a0","article-title":"Defects of B-Cell Lymphopoiesis and Bone-Marrow Myelopoiesis in Mice Lacking the CXC Chemokine PBSF\/SDF-1","volume":"382","author":"Nagasawa","year":"1996","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nature11885","article-title":"Haematopoietic Stem Cells and Early Lymphoid Progenitors Occupy Distinct Bone Marrow Niches","volume":"495","author":"Ding","year":"2013","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-Derived Nurse-Like Cells Protect Chronic Lymphocytic Leukemia B Cells From Spontaneous Apoptosis Through Stromal Cell-Derived Factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401602","article-title":"Overexpression of the Chemokine Receptor CXCR4 in B Cell Chronic Lymphocytic Leukemia is Associated With Increased Functional Response to Stromal Cell-Derived Factor-1 (SDF-1)","volume":"13","author":"Mohle","year":"1999","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01376-1","article-title":"CXCR4 Hyperactivation Cooperates With TCL1 in CLL Development and Aggressiveness","volume":"35","author":"Lewis","year":"2021","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical Outcomes and Prognostic Factors in Patients With Richter\u2019s Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278304","article-title":"The Complex Karyotype Landscape in Chronic Lymphocytic Leukemia Allows to Refine the Risk of Richter Syndrome Transformation","author":"Visentin","year":"2021","journal-title":"Haematologica"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30596","article-title":"Longterm Outcomes for Patients With Chronic Lymphocytic Leukemia Who Discontinue Ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.1200\/jco.2011.29.15_suppl.6508","article-title":"Activity and Tolerability of the Bruton\u2019s Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL): Interim Results of a Phase Ib\/II Study [Abstract]","volume":"29","author":"Byrd","year":"2011","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2017.35.15_suppl.7505","article-title":"Richter\u2019s Syndrome (RS) in Patients With Chronic Lymphocytic Leukemia (CLL) on Novel Agent Therapy [Abstract]","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological Features and Outcomes of Progression of CLL on the BCL2 Inhibitor Venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL Patients Treated With Sequential Kinase Inhibitor Therapy: A Real World Experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of Patients With CLL Sequentially Resistant to Both BCL2 and BTK Inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23841","article-title":"Poor Efficacy and Tolerability of R-CHOP in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Richter Transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as Single-Agent CD20 Immunotherapy in fludarabine-Refractory Chronic Lymphocytic Leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI Phase II Study of CHOP in Combination With Ofatumumab in Induction and Maintenance in Newly Diagnosed Richter Syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1182\/blood.V126.23.2951.2951","article-title":"A Single-Institution Retrospective Cohort Study of Patients Treated With R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia","volume":"126","author":"Rogers","year":"2015","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109064589","article-title":"Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin (Daunoxome), and Dexamethasone (Hyper-CVXD) Regimen in Richter\u2019s Syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11238","article-title":"Fractionated Cyclophosphamide, Vincristine, Liposomal Daunorubicin, and Dexamethasone Plus Rituximab and Granulocytemacrophage- Colony Stimulating Factor (GM-CSF) Alternating With Methotrexate and Cytarabine Plus Rituximab and GMCSF in Patients With Richter Syndrome or Fludarabine Refractory Chronic Lymphocytic Leukemia","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter\u2019s Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed\/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4108","article-title":"Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Cwynarski","year":"2012","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004865","article-title":"Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma-Type Richter Syndrome","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003726","article-title":"Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia and Richter's Transformation","volume":"5","author":"Lahoud","year":"2021","journal-title":"Blood Adv"},{"key":"B78","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.hemonc.2020.05.002","article-title":"Allogeneic Hematopoietic Cell Transplantation is an Effective Treatment for Patients With Richter Syndrome: A Systematic Review and Meta-Analysis","volume":"14","author":"Aulakh","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1182\/blood.V124.21.396.396","article-title":"The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed\/Refractory non Hodgkin\u2019s Lymphoma (NHL)","volume":"124","author":"Kuruvilla","year":"2014","journal-title":"Blood (ASH Annu Meet Abstracts)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-610782","article-title":"The Efficacy of Ibrutinib in the Treatment of Richter Syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1038\/bcj.2014.98","article-title":"Ibrutinib has Some Activity in Richter's Syndrome","volume":"5","author":"Giri","year":"2015","journal-title":"Blood Cancer J"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1159\/000477338","article-title":"Successful Treatment of Richter Transformation With Ibrutinib in a Patient With Chronic Lymphocytic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant","volume":"10","author":"Master","year":"2017","journal-title":"Case Rep Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002454","article-title":"Incidental Richter Transformation in Chronic Lymphocytic Leukemia Patients During Temporary Interruption of Ibrutinib","volume":"4","author":"Hampel","year":"2020","journal-title":"Blood Adv"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib Monotherapy for Treatment of Chronic Lymphocytic Leukaemia (ACE-CL-001): Analysis of the Richter Transformation Cohort of an Open-Label, Single-Arm, Phase 1-2 Study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol"},{"key":"B85","article-title":"Pirtobrutinib (LOXO-305), a Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Richter Transformation: Results From the Phase 1\/2 BRUIN Study.","volume":"5","author":"Mato","year":"2021","journal-title":"HemaSphere"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discovery"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0273","article-title":"E\u03bc-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma","volume":"25","author":"Lucas","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005734","article-title":"Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1","volume":"137","author":"Kohlhaas","year":"2021","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15440","article-title":"BCR Kinase Inhibitors, Idelalisib and Ibrutinib, are Active and Effective in Richter Syndrome","volume":"185","author":"Visentin","year":"2019","journal-title":"Br J Haematol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-In-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax Plus Dose-Adjusted R-EPOCH (VR-EPOCH) for Richter's Syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic Antitumor Immunity by Checkpoint Blockade is Enhanced by Ibrutinib, an Inhibitor of Both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and Activity of Ibrutinib in Combination With Nivolumab in Patients With Relapsed non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia: A Phase 1\/2a Study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1182\/blood-2021-154279","article-title":"Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients With Richter Transformation","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.24.13158","article-title":"CD19 and CD22 Expression Reciprocally Regulates Tyrosine Phosphorylation of Vav Protein During B Lymphocyte Signaling","volume":"94","author":"Sato","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059636","article-title":"CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"B98","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood.V71.1.13.13","article-title":"Detailed Studies on Expression and Function of CD19 Surface Determinant by Using B43 Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins","volume":"71","author":"Uckun","year":"1988","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape From CAR T-Cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discovery"},{"key":"B100","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and Efficacy of CD19-Targeted CAR T Cells With Concurrent Ibrutinib for CLL After Ibrutinib Failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-138904","article-title":"Safety and Efficacy of CD19-CAR T Cells in Richter\u2019s Transformation After Targeted Therapy for Chronic Lymphocytic Leukemia","volume":"136","author":"Benjamini","year":"2020","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical Activity of Axicabtagene Ciloleucel in Adult Patients With Richter Syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/hon.124_2629","article-title":"Phase I Clinical Trial of CD19-Targeted 19-28Z\/4-1BBL \u201cArmored\u201d CAR T Cells in Patients With Relapsed or Refractory NHL and CLL Including Richter Transformation","volume":"37","author":"Batlevi","year":"2019","journal-title":"Hematol Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828471","article-title":"Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation","volume":"12","author":"Ortiz-Maldonado","year":"2022","journal-title":"Front Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14570","article-title":"Phase I Study of Cord Blood-Derived Natural Killer Cells Combined With Autologous Stem Cell Transplantation in Multiple Myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br J Haematol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22121","article-title":"Hodgkin Transformation of Chronic Lymphocytic Leukemia: The M. D. Anderson Cancer Center Experience","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2141.2011.08907.x","article-title":"Hodgkin Lymphoma as Richter Transformation in Chronic Lymphocytic Leukaemia: A Retrospective Analysis of World Literature","volume":"156","author":"Bockorny","year":"2012","journal-title":"Br J Haematol"},{"key":"B111","article-title":"Hodgkin's Variant of Richter Transformation in Chronic Lymphocytic Leukemia; a Retrospective Study From the Israeli CLL Study Group","volume":"34","author":"Tadmor","year":"2014","journal-title":"Anticancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin Pulmonary Toxicity has a Negative Impact on the Outcome of Patients With Hodgkin\u2019s Lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/path.5795","article-title":"Artificial Intelligence Strategy Integrating Morphologic and Architectural Biomarkers Provides Robust Diagnostic Accuracy for Disease Progression in Chronic Lymphocytic Leukemia","volume":"256","author":"El Hussein","year":"2021","journal-title":"J Pathol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.003","article-title":"2-[18f]-FDG PET\/CT Role in Detecting Richter Transformation of Chronic Lymphocytic Leukemia and Predicting Overall Survival","volume":"21","author":"Albano","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002879","article-title":"Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter Syndrome","volume":"45","author":"Pontoizeau","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.crad.2021.06.001","article-title":"Chronic Lymphocytic Leukaemia and Richter\u2019s Transformation: Multimodal Review and New Imaging Paradigms","volume":"76","author":"Musanhu","year":"2021","journal-title":"Clin Radiol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.010","article-title":"Preclinical Specificity and Safety of UC-961, a First-in-Class Monoclonal Antibody Targeting ROR1","volume":"15","author":"Choi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B119","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients With Chronic Lymphocytic Leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 Targeting With the Antibody-Drug Conjugate VLS-101 is Effective in Richter Syndrome Patient-Derived Xenograft Mouse Models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2020.11.010","article-title":"U-RT1 - A New Model for Richter Transformation","volume":"23","author":"Schmid","year":"2021","journal-title":"Neoplasia"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01181-w","article-title":"BET Proteolysis Targeted Chimera-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma","volume":"35","author":"Fiskus","year":"2021","journal-title":"Leukemia"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010187","article-title":"Synergistic Efficacy of the Dual PI3K-\u03b4\/\u03b3 Inhibitor Duvelisib With the Bcl-2 Inhibitor Venetoclax in Richter Syndrome PDX Models","volume":"137","author":"Iannello","year":"2021","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 Chimeric Antigen Receptor T Cells are Active Against B- and T-Cell Lymphomas","volume":"132","author":"Scarf\u00f2","year":"2018","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664421","article-title":"A Prospective Investigation of Bispecific CD19\/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.829983\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T19:28:11Z","timestamp":1648409291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.829983\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":125,"alternative-id":["10.3389\/fonc.2022.829983"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.829983","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"article-number":"829983"}}